MX2010007502A - Compuestos de tienopiridazina, sus preparaciones, composiciones farmaceuticas y sus usos. - Google Patents
Compuestos de tienopiridazina, sus preparaciones, composiciones farmaceuticas y sus usos.Info
- Publication number
- MX2010007502A MX2010007502A MX2010007502A MX2010007502A MX2010007502A MX 2010007502 A MX2010007502 A MX 2010007502A MX 2010007502 A MX2010007502 A MX 2010007502A MX 2010007502 A MX2010007502 A MX 2010007502A MX 2010007502 A MX2010007502 A MX 2010007502A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- pharmaceutical compositions
- preparations
- thienopyridazine
- thienopyridazine compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona a compuestos de la Fórmula (I), sus sales o hidratos farmacéuticamente aceptables, en donde R1 y R2 son independientemente H ó alquilo C1-4, R3 es un anillo saturado o insaturado de 5- ó 6- miembros conteniendo N, S ú O ó sus isómeros ópticos, R4 es un halofenilo monosustituido o bisustituido en cualquier posición. La presente invención proporciona los métodos de preparación de estos compuestos, las composiciones farmacéuticas conteniendo estos compuestos y los usos de éstos compuestos, particularmente en el tratamiento del cáncer. (ver fórmula (I)).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810000936 | 2008-01-08 | ||
CN2009100003371A CN101481380B (zh) | 2008-01-08 | 2009-01-06 | 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 |
PCT/CN2009/000021 WO2009092278A1 (zh) | 2008-01-08 | 2009-01-07 | 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010007502A true MX2010007502A (es) | 2010-10-15 |
Family
ID=40878690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010007502A MX2010007502A (es) | 2008-01-08 | 2009-01-07 | Compuestos de tienopiridazina, sus preparaciones, composiciones farmaceuticas y sus usos. |
Country Status (11)
Country | Link |
---|---|
US (3) | US8318740B2 (es) |
EP (1) | EP2241569B1 (es) |
JP (1) | JP5456694B2 (es) |
KR (1) | KR101512530B1 (es) |
CN (1) | CN101481380B (es) |
AU (1) | AU2009207968B2 (es) |
BR (1) | BRPI0907228B1 (es) |
CA (1) | CA2711629C (es) |
MX (1) | MX2010007502A (es) |
RU (1) | RU2494103C2 (es) |
WO (1) | WO2009092278A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2587509T3 (es) * | 2009-09-18 | 2016-10-25 | Zhanggui Wu | Derivados de tieno[2,3-d]piridazina y uso terapéutico de los mismos para la inhibición de proteína cinasa |
CN105358154A (zh) | 2013-05-10 | 2016-02-24 | 尼普斯阿波罗有限公司 | Acc抑制剂和其用途 |
JP6417401B2 (ja) | 2013-05-10 | 2018-11-07 | ギリアド アポロ, エルエルシー | Acc阻害剤及びその使用 |
BR112015028214A2 (pt) | 2013-05-10 | 2017-07-25 | Nimbus Apollo Inc | inibidores de acc e usos dos mesmos |
AU2014262546B2 (en) | 2013-05-10 | 2018-11-08 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
NZ754039A (en) * | 2013-06-26 | 2021-06-25 | Abbvie Inc | Primary carboxamides as btk inhibitors |
CN103288614B (zh) * | 2013-06-27 | 2014-09-17 | 中国科学院昆明植物研究所 | 具有抗肿瘤活性的间苯三酚类化合物及其药物组合物 |
WO2015013579A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Compositions to improve the therapeutic benefit of bisantrene |
CN103694217A (zh) * | 2013-12-20 | 2014-04-02 | 华东师范大学 | 一种2,4-二取代噻吩衍生物及其制备方法和应用 |
AU2021206201A1 (en) * | 2020-01-07 | 2022-08-18 | Shanghai Huayu Biotechnology Co., Ltd. | Combination cancer therapy using CHK inhibitor |
US20230183259A1 (en) * | 2020-04-17 | 2023-06-15 | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory | Crystal Form Of Thiofuran Pyridazine Compound, Preparation Method Therefor And Application Thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO5200835A1 (es) * | 1999-09-28 | 2002-09-27 | Bayer Corp | Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis |
ES2314443T3 (es) * | 2003-08-15 | 2009-03-16 | Astrazeneca Ab | Tiofenos sustituidos y sus usos. |
CN100584840C (zh) * | 2004-01-05 | 2010-01-27 | 阿斯利康(瑞典)有限公司 | 取代杂环化合物及其应用 |
CA2563990A1 (en) * | 2004-05-04 | 2005-11-10 | Sharada Shenvi Labadie | Thienopyridazines as ikk inhibitors |
KR20080009200A (ko) * | 2005-04-06 | 2008-01-25 | 아스트라제네카 아베 | 치환된 헤테로사이클 및 이것의 chk1, pdk1 및pak 억제제로서의 용도 |
EP2038289A2 (en) * | 2006-04-21 | 2009-03-25 | Amgen Inc. | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
US7851622B2 (en) * | 2007-04-25 | 2010-12-14 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists |
WO2009003911A1 (en) * | 2007-06-29 | 2009-01-08 | 4Sc Ag | Thiophene-imidazopyridines |
-
2009
- 2009-01-06 CN CN2009100003371A patent/CN101481380B/zh active Active
- 2009-01-07 US US12/349,888 patent/US8318740B2/en active Active
- 2009-01-07 WO PCT/CN2009/000021 patent/WO2009092278A1/zh active Application Filing
- 2009-01-07 CA CA2711629A patent/CA2711629C/en active Active
- 2009-01-07 EP EP09703313A patent/EP2241569B1/en active Active
- 2009-01-07 JP JP2010541010A patent/JP5456694B2/ja active Active
- 2009-01-07 AU AU2009207968A patent/AU2009207968B2/en active Active
- 2009-01-07 BR BRPI0907228-4A patent/BRPI0907228B1/pt active IP Right Grant
- 2009-01-07 KR KR1020107017631A patent/KR101512530B1/ko active IP Right Grant
- 2009-01-07 MX MX2010007502A patent/MX2010007502A/es active IP Right Grant
- 2009-01-07 US US12/811,898 patent/US8962626B2/en active Active
- 2009-01-07 RU RU2010128221/04A patent/RU2494103C2/ru active
-
2012
- 2012-11-02 US US13/668,197 patent/US9249154B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2009207968A1 (en) | 2009-07-30 |
CA2711629A1 (en) | 2009-07-30 |
BRPI0907228B1 (pt) | 2021-08-03 |
US9249154B2 (en) | 2016-02-02 |
WO2009092278A1 (zh) | 2009-07-30 |
KR101512530B1 (ko) | 2015-04-15 |
RU2494103C2 (ru) | 2013-09-27 |
AU2009207968B2 (en) | 2014-04-24 |
KR20100117069A (ko) | 2010-11-02 |
CA2711629C (en) | 2017-10-24 |
EP2241569A1 (en) | 2010-10-20 |
BRPI0907228A2 (pt) | 2015-07-14 |
US20130143887A1 (en) | 2013-06-06 |
US8318740B2 (en) | 2012-11-27 |
CN101481380B (zh) | 2012-10-17 |
EP2241569B1 (en) | 2012-05-23 |
RU2010128221A (ru) | 2012-02-20 |
US20110009415A1 (en) | 2011-01-13 |
EP2241569A4 (en) | 2011-01-12 |
CN101481380A (zh) | 2009-07-15 |
JP5456694B2 (ja) | 2014-04-02 |
US8962626B2 (en) | 2015-02-24 |
WO2009092278A8 (zh) | 2010-07-22 |
JP2011508750A (ja) | 2011-03-17 |
US20090275585A1 (en) | 2009-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010007502A (es) | Compuestos de tienopiridazina, sus preparaciones, composiciones farmaceuticas y sus usos. | |
UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
ECSP109934A (es) | Compuesto - 946 | |
HUP0303271A2 (hu) | Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására | |
UY30107A1 (es) | Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones | |
GEP20156389B (en) | Oxazolidin-2-one compounds and their usage as pi3ks inhibitors | |
TN2017000374A1 (en) | TGF-β INHIBITORS | |
CO6741203A2 (es) | Derivados de biciclo[3,2,1]octilamida y sus usos | |
GEP20156289B (en) | New aminopyrazoloquinazolines | |
AR053162A1 (es) | Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma. | |
UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
UY29234A1 (es) | Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones. | |
MX2009004699A (es) | Compuestos de piridinona. | |
AU2009215534A8 (en) | Compounds that are ERK inhibitors | |
ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
CL2007003604A1 (es) | Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer. | |
BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
MX2009012613A (es) | Tiazoles substituidos por heteroarilo y su uso como agentes antivirales. | |
AR094553A1 (es) | Formas de oxadiazolpirazina | |
SV2009003389A (es) | Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer | |
CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |